Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir Prophylaxis for CMV in Pediatric HCT
NCT05711667Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jul 2024
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of letermovir in cytomegalovirus infection (CMV) (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Clinically significant cytomegalovirus (CMV) infection at 14 weeks. Started Jul 2024; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05711667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05711667.